Park Therapeutics
Park Therapeutics is a privately held, clinical-stage pharmaceutical company developing a single first-in-class investigational New Chemical Entity for the treatment of pain, currently described as Phase III-ready, and based in Morristown, United States.
- Company typePrivate
- Founded2020
- HeadquartersMorristown, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Park Therapeutics does
Park Therapeutics is a privately held, clinical-stage pharmaceutical company founded in 2020 and headquartered in Morristown, United States. The company's stated focus is the development of a single, unique, first-in-class investigational New Chemical Entity (NCE) intended for the treatment of pain, with the asset characterized as Phase III-ready.
The company's product portfolio, as disclosed, consists of one late-stage clinical asset — a small-molecule NCE positioned as first-in-class in the pain therapeutic area. No additional pipeline candidates, platform technology, mechanism-of-action detail, formulation work, or manufacturing partnerships are described in the available source material. The Phase III-ready designation implies that preclinical work, Phase I/II development, and CMC/regulatory preparation necessary to enter pivotal trials have been completed or are substantially complete, though no specific trial identifiers, IND numbers, or regulatory milestones are confirmed in the data.
The business model is consistent with a virtual or semi-virtual clinical-stage biotech: a small team (1-10 employees) advancing a single asset toward late-stage clinical development and, by implication in this asset class, eventual out-licensing, partnership, or trade-sale monetization rather than direct commercialization. No pricing model, go-to-market motion, customer agreements, or revenue mechanics are disclosed. The company website (parktherapeutics.com) currently renders a verification placeholder page, which limits extraction of any further firmographic, ownership, or investor detail.
Park Therapeutics firmographics
Firmographics- Name
- Park Therapeutics
- Website
- https://parktherapeutics.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Park Therapeutics is a privately held, clinical-stage pharmaceutical company developing a single first-in-class investigational New Chemical Entity for the treatment of pain, currently described as Phase III-ready, and based in Morristown, United States.
- Ownership category
- akta.pro rank
Park Therapeutics industry classification
Industry- Product category
- Pain Therapeutics
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
Keywords
Where Park Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Morristown
- HQ country
- United States
- HQ region
- North America
Markets served
Park Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Park Therapeutics product offering
Product offeringCore offering
Park Therapeutics is developing a unique, first-in-class, investigational New Chemical Entity (NCE) for the treatment of pain. The asset is Phase III-ready, indicating late-stage clinical development within the pain therapeutics space, but the company is not yet commercializing a marketed product.
Differentiator
Problem solved
Functional benefit
Products and services
- Investigational NCE for pain treatment A unique, first-in-class, investigational New Chemical Entity (NCE) being developed for the treatment of pain. The asset is Phase III-ready, positioning it for late-stage clinical execution, regulatory filing, and eventual out-licensing, partnership, or commercialization in the pain therapeutics market. Intended for pharmaceutical partners, payers of pain therapeutics, and ultimately patients suffering from pain conditions requiring novel analgesic mechanisms.
Companies that use Park Therapeutics
Customer profileIdeal customer profiles1 record
Park Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Park Therapeutics partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
Park Therapeutics competitors and assessment
Company assessmentEmerging players
- Aptinyx: Clinical-stage biotech developing NMDA receptor modulators for pain and CNS disorders, with overlapping novel-mechanism pain therapeutics development as Park Therapeutics.
Direct peers
- Cara Therapeutics: Clinical-stage company developing novel peripherally-acting kappa opioid receptor agonists for pain and pruritus, with a comparable late-stage pain therapeutics focus.
- Vertex Pharmaceuticals: Developed suzetrigine (VX-548), a first-in-class non-opioid NaV1.8 inhibitor for acute pain that reached FDA approval, making Vertex the most directly comparable late-stage pain NCE developer to Park Therapeutics.
- Trevena: Clinical-stage pain therapeutics company developing novel CNS-acting analgesics (e.g., oliceridine), making it a directly comparable single-indication pain NCE developer.
- Centrexion Therapeutics: Clinical-stage pain therapeutics developer focused on non-opioid treatments for chronic pain, directly comparable to a Phase III-ready NCE pain asset.
- Tonix Pharmaceuticals: Clinical-stage CNS-focused company with pain and neurology pipeline assets, broadly comparable as a small-cap single-indication NCE developer.
- Collegium Pharmaceutical: Specialty pharmaceutical company focused on pain management, including responsible opioid alternatives and CNS-acting analgesics, directly comparable in therapeutic focus.
Broad incumbents
- Pfizer: Major pharmaceutical incumbent with a substantial pain therapeutics franchise (including Lyrica and ongoing non-opioid programs), making it a broad incumbent peer and a likely acquirer profile for late-stage pain NCEs.
- Regeneron Pharmaceuticals: Major biopharma with pain-related antibody and gene therapy pipeline programs, comparable as a broad incumbent with scale and capital to compete in or acquire pain therapeutics.
- Eli Lilly: Large pharmaceutical company with active pain and CNS pipeline programs, broadly comparable as a potential strategic acquirer or competitor in the pain therapeutics space.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
Park Therapeutics social profiles
Digital presencePark Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Park Therapeutics leadership team
Management profileNumber of profiles
Park Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Park Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Park Therapeutics
What does Park Therapeutics do?
Park Therapeutics is developing a unique, first-in-class, investigational New Chemical Entity (NCE) for the treatment of pain. The asset is Phase III-ready, indicating late-stage clinical development within the pain therapeutics space, but the company is not yet commercializing a marketed product.
Is Park Therapeutics a public or private company?
Park Therapeutics is a private company. It is classified as unknown and is currently operating.
When was Park Therapeutics founded?
Park Therapeutics was founded in 2020. It employs 1 to 10 people.
Where is Park Therapeutics based?
Park Therapeutics is headquartered in Morristown, United States, in the North America region.
Who are Park Therapeutics's main competitors?
Aptinyx is listed as an emerging player. Direct peers are Cara Therapeutics, Vertex Pharmaceuticals, Trevena, Centrexion Therapeutics, Tonix Pharmaceuticals and Collegium Pharmaceutical. Broad incumbents are Pfizer, Regeneron Pharmaceuticals and Eli Lilly.
Does Park Therapeutics have an API?
No public API is recorded for Park Therapeutics.
What industry is Park Therapeutics in?
Park Therapeutics's product category is Pain Therapeutics. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 54171 and its SIC code is 2833.